1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Cystic Fibrosis Market, By Drug Class
5.1 Introduction
5.2 Pancreatic Enzyme Supplements
5.3 Mucolytic
5.4 Bronchodilators
5.5 Antibiotics
5.6 Cystic Fibrosis Transmembrane Conductance Regulator Modulators
5.7 Other Drug Classes
6 Global Cystic Fibrosis Market, By Treatment Method
6.1 Introduction
6.2 Medication
6.3 Devices
7 Global Cystic Fibrosis Market, By Route of Administration
7.1 Introduction
7.2 Oral
7.3 Inhaled
8 Global Cystic Fibrosis Market, By Distribution Channel
8.1 Introduction
8.2 Hospital
8.3 Drug Stores
8.4 Retail Pharmacies
8.5 Other Distribution Channels
9 Global Cystic Fibrosis Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Pharmaxis Ltd
11.2 Gilead Sciences, Inc.
11.3 Teva Pharmaceuticals
11.4 Genentech Inc
11.5 AbbVie Inc.
11.6 Mylan N.V
11.7 Viatris Inc.
11.8 Novartis AG
11.9 Allergan PLC
11.10 Pfizer Inc
11.11 Nestle Health Science
11.12 Hoffmann-La Roche AG
11.13 BayerAG
11.14 Vertex Pharmaceuticals Incorporated
11.15 AstraZeneca
11.16 Chiesi Farmaceutici SpA
11.17 Horizon Therapeutic Plc.
List of Tables
Table 1 Global Cystic Fibrosis Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
Table 3 Global Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
Table 4 Global Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
Table 5 Global Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
Table 6 Global Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 7 Global Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
Table 8 Global Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 9 Global Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
Table 10 Global Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
Table 11 Global Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
Table 12 Global Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 13 Global Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
Table 14 Global Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
Table 15 Global Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 16 Global Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
Table 17 Global Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 18 Global Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 19 Global Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 20 North America Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
Table 21 North America Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
Table 22 North America Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
Table 23 North America Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
Table 24 North America Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
Table 25 North America Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 26 North America Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
Table 27 North America Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 28 North America Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
Table 29 North America Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
Table 30 North America Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
Table 31 North America Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 32 North America Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
Table 33 North America Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
Table 34 North America Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 35 North America Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
Table 36 North America Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 37 North America Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 38 North America Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 39 Europe Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
Table 40 Europe Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
Table 41 Europe Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
Table 42 Europe Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
Table 43 Europe Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
Table 44 Europe Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 45 Europe Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
Table 46 Europe Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 47 Europe Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
Table 48 Europe Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
Table 49 Europe Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
Table 50 Europe Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 51 Europe Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
Table 52 Europe Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
Table 53 Europe Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 54 Europe Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
Table 55 Europe Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 56 Europe Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 57 Europe Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 58 Asia Pacific Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
Table 59 Asia Pacific Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
Table 60 Asia Pacific Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
Table 61 Asia Pacific Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
Table 62 Asia Pacific Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
Table 63 Asia Pacific Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 64 Asia Pacific Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
Table 65 Asia Pacific Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 66 Asia Pacific Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
Table 67 Asia Pacific Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
Table 68 Asia Pacific Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
Table 69 Asia Pacific Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 70 Asia Pacific Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
Table 71 Asia Pacific Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
Table 72 Asia Pacific Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 73 Asia Pacific Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
Table 74 Asia Pacific Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 75 Asia Pacific Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 76 Asia Pacific Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 77 South America Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
Table 78 South America Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
Table 79 South America Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
Table 80 South America Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
Table 81 South America Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
Table 82 South America Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 83 South America Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
Table 84 South America Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 85 South America Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
Table 86 South America Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
Table 87 South America Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
Table 88 South America Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 89 South America Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
Table 90 South America Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
Table 91 South America Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 92 South America Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
Table 93 South America Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 94 South America Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 95 South America Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 96 Middle East & Africa Cystic Fibrosis Market Outlook, By Country (2021-2030) ($MN)
Table 97 Middle East & Africa Cystic Fibrosis Market Outlook, By Drug Class (2021-2030) ($MN)
Table 98 Middle East & Africa Cystic Fibrosis Market Outlook, By Pancreatic Enzyme Supplements (2021-2030) ($MN)
Table 99 Middle East & Africa Cystic Fibrosis Market Outlook, By Mucolytic (2021-2030) ($MN)
Table 100 Middle East & Africa Cystic Fibrosis Market Outlook, By Bronchodilators (2021-2030) ($MN)
Table 101 Middle East & Africa Cystic Fibrosis Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 102 Middle East & Africa Cystic Fibrosis Market Outlook, By Cystic Fibrosis Transmembrane Conductance Regulator Modulators (2021-2030) ($MN)
Table 103 Middle East & Africa Cystic Fibrosis Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 104 Middle East & Africa Cystic Fibrosis Market Outlook, By Treatment Method (2021-2030) ($MN)
Table 105 Middle East & Africa Cystic Fibrosis Market Outlook, By Medication (2021-2030) ($MN)
Table 106 Middle East & Africa Cystic Fibrosis Market Outlook, By Devices (2021-2030) ($MN)
Table 107 Middle East & Africa Cystic Fibrosis Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 108 Middle East & Africa Cystic Fibrosis Market Outlook, By Oral (2021-2030) ($MN)
Table 109 Middle East & Africa Cystic Fibrosis Market Outlook, By Inhaled (2021-2030) ($MN)
Table 110 Middle East & Africa Cystic Fibrosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 111 Middle East & Africa Cystic Fibrosis Market Outlook, By Hospital (2021-2030) ($MN)
Table 112 Middle East & Africa Cystic Fibrosis Market Outlook, By Drug Stores (2021-2030) ($MN)
Table 113 Middle East & Africa Cystic Fibrosis Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 114 Middle East & Africa Cystic Fibrosis Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
| ※参考情報 嚢胞性線維症（Cystic Fibrosis）は、遺伝性の疾患で、主に呼吸器系や消化器系に影響を与える病気です。主な原因はCFTR遺伝子の変異で、この遺伝子は体内で塩分と水分のバランスを調整するためのタンパク質をコードしています。このタンパク質が正常に機能しないため、体内の粘液が異常に粘り気を帯び、様々な臓器で障害を引き起こします。 嚢胞性線維症にはいくつかの異なるタイプが存在します。代表的なものとして、典型型と非典型型があります。典型型では、呼吸器や消化器に顕著な症状が現れ、特に小児期に診断されることが多いです。一方、非典型型では症状が軽度であったり、診断が遅れることがあります。また、嚢胞性線維症は遺伝子の変異の種類によっても分類され、特に重篤度や治療法にも影響を与えます。 嚢胞性線維症の主な症状は、慢性的な咳、反復的な肺感染、喘鳴、そして消化不良が含まれます。これらの症状は、患者さんの生活の質に大きく影響を与え、特に呼吸器症状は生命を脅かすこともあります。また、消化器症状として、栄養の吸収不良による体重減少や、膵臓の機能不全が見られます。 診断は通常、乳幼児の新生児スクリーニングや、汗の塩分濃度の測定、遺伝子検査を通じて行われます。新生児スクリーニングでは、早期に発見することで適切な治療を開始できるため、重要な役割を果たしています。特に新生児期に診断されることで、治療の効果を最大限に引き出すことが可能となります。 治療には、肺機能を改善するための吸入療法、抗生物質、気道クリーニング法などが含まれます。これらの治療法は粘液を薄くし、呼吸を楽にすることを目的としています。また、消化器症状には、膵酵素補充療法や特別な食事療法が行われます。近年では、遺伝子治療や新しい薬剤の開発も進んでおり、患者さんの生活の質を向上させる可能性が期待されています。 関連技術としては、呼吸療法やリハビリテーションが挙げられます。これらは、肺機能の維持や改善を目指したものです。また、最新の技術として遺伝子編集技術や、CFTR修復薬などの研究が進んでおり、病気の根本的な治療に向けたアプローチが模索されています。これにより、将来的にはより効果的な治療法の確立が期待されています。 さらに、患者の生活全体を支えるための心理的支援や社会的サポートも重要です。嚢胞性線維症は慢性疾患であるため、患者とその家族は長期にわたる支援を必要とします。こうしたサポートは、医療チームの一員としての常に行われるべきです。 まとめると、嚢胞性線維症は遺伝性の病気であり、さまざまな治療法やテクノロジーがその管理において重要な役割を果たしています。これまでの研究により、患者さんにとっての治療選択肢は増えつつありますが、まだ多くの課題が残っています。今後の研究と技術の進歩により、嚢胞性線維症の治療がより良い方向へ進展することが期待されています。これにより、患者さんの生活の質が向上し、病気に対する理解も深まることができるでしょう。 |
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
